Figure 4
From: Phase II study of the farnesyltransferase inhibitor R115777 in advanced melanoma (CALGB 500104)
IFŇγ production by peripheral blood lymphocytes analyzed ex vivo. PBMC obtained pre-treatment and during week 7 of therapy were analyzed for T cell function by stimulating with the superantigen SEA and measuring IFN-γ production by ELISA. The post-versus pre-treatment values for the group of samples were statistically different as measured using a paired t-test (p<0.05).